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Abstract
Background: Expression of transglutaminase 2 (TGase 2) is related to invasion and resistance to chemotherapeutic
agents in several cancer cells. However, there has been only limited clinical validation of TGase 2 as an
independent prognostic marker in cancer.
Methods: The significance of TGase 2 expression as an invasive/migratory factor was addressed by in vitro assays
employing down-regulation of TGase 2. TGase 2 expression as a prognostic indicator was assessed in 429 Korean
patients with early-stage non-small cell lung cancer (NSCLC) by immunohistochemical staining.
Results: TGase 2 expression increased the invasive and migratory properties of NSCLC cells in vitro, which might
be related to the induction of MMP-9. In the analysis of the immunohistochemical staining, TGase 2 expression in
tumors was significantly correlated with recurrence in NSCLC (p = 0.005) or in the non-adenocarcinoma subtype (p
= 0.031). Additionally, a multivariate analysis also showed a significant correlation between strong TGase 2
expression and shorter disease-free survival (DFS) in NSCLC (p = 0.029 and HR = 1.554) and in the non-
adenocarcinoma subtype (p = 0.030 and HR = 2.184). However, the correlation in the adenocarcinoma subtype
was not significant.
Conclusions: TGase 2 expression was significantly correlated with recurrence and shorter DFS in NSCLC, especially
in the non-adenocarcinoma subtype including squamous cell carcinoma.
Background
Lung cancer is the leading cause of cancer-related death,
accounting for approximately 29% of all cases (Cancer Stat
Fact Sheets, http://www.seer.cancer.gov); approximately
85% of lung cancer cases are non-small cell lung cancer
(NSCLC). There are several different subtypes of NSCLC,
among which are adenocarcinoma and squamous cell can-
cer. Currently, the NSCLC subtypes are regarded as a sin-
gle disease, however, the adenocarcinoma and non-
adenocarcinoma subtypes are regarded as being separate
entities, owing to their different responses to recently
developed agents such as pemetrexed, gefitinib, bevaciuzu-
mab, and crizotinib, which are more effective in adenocar-
cinoma [1-3]. Accordingly, identification of the molecular
differences between these tumor types will have a signifi-
cant impact on the design of novel therapies that can
improve treatment outcomes.
Transglutaminase 2 (TGase 2) is a multifunctional
protein that can bind and hydrolyze GTP as well as cat-
alyze covalent cross-links [4]. The biological role of
TGase 2 in the development of resistance to cisplatin
and doxorubicin in several cancer cells has drawn con-
siderable attention [5-9]. Another biological role of
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any medium, provided the original work is properly cited.TGase 2, this one in cancer metastasis and invasion, was
reported for breast, pancreatic, and ovarian cancers
[10-13]. However, the role of TGase 2 expression as an
independent prognostic factor has not been well eluci-
dated, except for a study on ovarian cancer [11]. More-
over, the possibility that TGase 2 has different roles in
different subtypes of any cancer has never been sug-
gested. Accordingly, in the present study, after first test-
ing the biological role of TGase 2 in invasion and
migration with NSCLC cell lines, its role as a prognostic
indicator in NSCLC was investigated in an immunohis-
tochemical study on early-stage NSCLC tissues.
Materials and methods
Cell lines
Human squamous lung cancer cell lines H1703 and
HCC-95 were obtained from the Korean Cell Line Bank
and maintained in RPMI 1640 supplemented with 10%
fetal bovine serum (Thermo Fisher Scientific Hyclone,
Logan, UT), 1 mM sodium pyruvate, and 100 U/mL
penicillin-streptomycin at 37°C in a humidified 5% CO2
incubator.
Scratch cell migration assay
Parental cells or cells transfected with control or small
interfering RNAs (siRNAs) targeting TGase 2 were
grown to confluence, at which time they were scratched
with a pipette tip. Cell lines not treated with siRNA
were starved by incubation overnight in serum-free
medium. The cultures were rinsed to remove detached
cells and then incubated for 24-48 h. After incubation,
the cells were fixed and visualized by light microscopy.
These assays were performed three times.
Matrigel cell invasion assay
The invasive behavior of cells was determined in vitro
using BioCoat Matrigel Invasion Chamber (BD Bios-
ciences, Bedford, MA) inserts. The cells were trypsi-
nized, and the resulting cell pellets were resuspended in
serum-free medium at a final concentration of 1 × 10
5
cells, after which 500 μL of suspended cells was added
to the insert with 750 μLo fc o m p l e t em e d i u m .A f t e r2 4
or 48 h incubation, the cells that passed through the fil-
ter to the underside of the membrane were stained and
counted under a light microscope. Ten fields of cells
were counted for each well, and the mean number of
cells per field was calculated. Each experiment was per-
formed in triplicate and repeated at least two times.
Transfection
TGase 2 was knocked down by introducing an siRNA
duplex targeting human TGM2 mRNA (5’-AAG AGC
GAG AUG AUC UGG AAC-3’) into cells using Fugene
6 (Roche, Mannheim, Germany) according to the
manufacturer’s instructions. Briefly, cells were seeded at
ad e n s i t yo f3×1 0
5 per well in a six-well plate. When
the cells reached about 60% confluence, 400 μLo fa n
siRNA-Fugene 6 mixture was added, and the cells were
incubated for 48 h in a 5%CO2 incubator.
Western blot analysis
Equal amounts of each cell lysate were electrophoresed
on sodium dodecyl sulfate-polyacrylamide gels, after
which resolved proteins were transferred to polyvinyli-
dene difluoride membranes. The membranes were incu-
bated with various primary antibodies diluted in TBST
(20 mM Tris, 134 mM NaCl, 0.02% Tween 20). The pri-
mary antibodies were then detected with horseradish
peroxidase-conjugated secondary antibodies followed by
exposure to an enhanced chemiluminescence reagent.
The antibodies for MMP-9, MMP-2 and Vimentin were
purchased from Santa Cruz Biotechnology (Santa Cruz,
California); those for E-cadherin and b-actin were
obtained from Abcam (Cambridge, MA).
Gelatin zymography
MMP-9 activity in the cultured cells was measured
using gelatin-gel zymography. The ten-fold-concentrated
culture medium was electrophoretically resolved by 7.5%
SDS-PAGE containing 0.1% gelatin under the non-redu-
cing condition. The gel was washed in 2.5% Triton X-
100 for 30 min to remove SDS and incubated overnight
a t3 7 ° Ci n5 0m MT r i s - C l ,p H7 . 5 ,a n d5m MC a C l 2.
After Coomassie blue staining and destaining of the gel,
the MMP-9 activity was detected as a clear band on a
dark blue background.
NSCLC cancer tissues and other human tissues
A total of 429 NSCLC cases for which surgery had been
performed at the Asan Medical Center (Seoul, Korea)
between 2000 and 2003 were selected from the archives
of the Department of Pathology, and tissue arrays were
prepared. The use of relevant human archival tissues
was approved by the Institutional Review Board. All
available histological slides, which had been routinely
stained with hematoxylin and eosin (H&E), were
reviewed. As controls, a variety of human tissue array
sections (BB6, CCA3, CC4, CSA3, CBA3 and CDA2),
purchased from SuperBioChip Laboratories (http://www.
tissue-array.com), were used.
Immunohistochemical staining of TGase 2 in NSCLC
Immunohistochemical staining was performed using an
Ultravision LP Detection kit (Lab Vision, USA). The tis-
sue sections were deparaffinized with xylene, and anti-
gen retrieval was accomplished by autoclaving the slides
in 10 mM Tris (pH 9.0) and 1 mM EDTA for 15 min.
After fixing in 95% ethanol, the slides were treated with
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Page 2 of 103% hydrogen peroxide, incubated with Ultra V block
solution for 15 min, and then incubated with anti-
T G a s e2p r i m a r ya n t i b o d y( N e o M a r k e r s ,F r e m o n t ,C A )
at a dilution of 1:200 for 1 h at room temperature. After
washing in TBST, the slides were treated with primary
antibody enhancer for 10 min and then incubated with
HRP-conjugated secondary antibody for 15 min. The
slides were then washed with TBST, incubated with
DAB chromogen, and counterstained with Mayer’s
Hematoxylin (Dako Cytomation, Glostrup, Denmark).
Negative controls, from which the primary antibody had
been omitted, were run in parallel. Immunostaining was
graded semi-quantitatively, considering both staining
intensity and the percentage of positive tumor cells, by
two study pathologists blinded to the clinicopathologic
variables. The staining intensity was scored on a 0-to-3
scale: 0, no staining of cancer cells; 1, weak staining; 2,
moderate staining; 3, strong staining. Also, the percen-
tage of stained tumor cells was scored on a 0-to-3 scale:
0, <10%; 1, 10%-49%; 2, 50%-75%; 3, >75%. The two
scores were multiplied, and TGase 2 expression was
defined as negative, if the product was 0; intermediate, if
the product was 1-3; and strong, if the product was 4 or
more.
Expression of TGase 2 was found in cells of normal
structure, specifically in smooth muscle and blood vessel
endothelial cells. However, there was no such expression
in alveolar or bronchial epithelial cells.
Statistical analysis
The Chi-square test was used to examine differences in
TGase 2 immunoreactivity among the groups. The
Kaplan-Meier method was employed to estimate survival
distributions, and the survival curves were compared
using the log-rank test. Values of p < 0.05 were consid-
ered statistically significant.
For the purpose of determining associations between
TGase 2 over-expression and clinicopathologic variables,
a Chi-square or Fisher’s exact test was applied. The Cox
proportional hazard regression model was employed for
univariate and multivariate analyses of the relationship
between DFS and clinicopathologic variables or TGase 2
expression. In the multivariate analyses, the variables T-
stage, N-stage and histologic type were included as co-
variates. In analyses of the non-adenocarcinoma subtype,
clinical stage, histologic type and differentiation status
were considered as co-variates. All of the statistical ana-
lyses were performed using SPSS software (version 18).
Results
The question of whether TGase 2 expression confers a
metastatic phenotype on lung cancer cells was addressed
using two NSCLC cell lines: H1703 and HCC-95. TGase
2 was expressed at high levels in the H1703 cells, but
was barely detectable in the HCC-95 cells, as deter-
mined by Western blot analysis and reverse transcrip-
tion-polymerase chain reaction (RT-PCR) (Additional
File 1, Figure S1A). RT-PCR and Western blot analysis
showed that TGM2 siRNA reduced TGase 2 expression
in the H1703 cells (Additional File 1, Figure S1A). In
addition, TGase 2 down-regulation reduced nuclear fac-
tor B( N F - B) activity in the H1703 cells (Additional
File 1, Figure S1B), as we had previously demonstrated
for H1299 [9].
Because increased cell motility and invasion are
important features of metastatic cancer cells, we com-
pared the H1703 and HCC-95 cells for invasiveness,
employing a Matrigel invasion assay. As shown in Fig-
ures 1A and 1B, the H1703 cells exhibited greater inva-
siveness than the HCC-95 cells, suggesting that
invasiveness might be related to TGase 2-expression
levels in NSCLC. To further investigate the role of
TGase 2, we transiently transfected H1703 cells with
TGM2 siRNA to knock down the TGase 2 level. Nota-
bly, siRNA-mediated TGase 2 knockdown significantly
reduced the invasiveness of the H1703 cells (Figures 1C
and 1D). H1703 cells exhibited greater migration than
the HCC-95 cells (Figure 1E-1F), and knockdown of
TGase 2 by siRNA also reduced the migration of H1703
(Figure 1G-1H).
Further experiments concerning the relationships
between TGase 2 expression and MMPs or EMT mar-
kers were performed, and it was found that TGase 2
down-regulation by TGM2 siRNA is related to down-
regulation of MMP-9 but not of MMP-2 (Additional
File 2, Figure S2), suggesting that TGase 2’s role in inva-
sion and migration might be via the regulation of MMP-
9. This is consistent with the previous result for epider-
moid carcinoma, a skin cancer [14]. However, in ovarian
cancer, MMP-2 rather than MMP-9 regulation by
TGase 2 has been reported [13], indicating that different
MMPs are regulated by TGase 2 in different types of
cancer. The levels of epithelial-mesenchymal transition
(EMT) markers such as Vimentin and E-cadherin were
not changed by down-regulation of TGase 2 in NCI-
H1703 cells (Additional File 2, Figure S2).
To determine the importance of TGase 2 as a prog-
nostic factor in NSCLC cancer patients, we immunos-
tained tissue arrays collected from Korean patients with
early-stage NSCLC (Figure 2). Data on the 429 patients
are listed in Table 1. All of the patients had undergone
curative surgical resection by lobectomy (74.7%), pneu-
monectomy (16.4%), or bilobectomy (7.5%). About
51.5% of patients were stage I; 23.8% stage II, and 24.7%
stage III (Table 1). The median follow-up was 62
months, in a 26-81 month range. The post-resection
recurrence rate was about 40%. Histologically, strong
TGase 2 expression was also detected in smooth muscle
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Page 3 of 10Figure 1 TGase 2 expression is associated with increased invasion or migration of NSCLC cells. The levels of invasiveness for the H1703
and HCC-95 cells were compared in a Matrigel invasion assay system (A and B). Representative fields of cells that migrated through the Matrigel
to the underside of the membrane were either photographed (A) or counted randomly in 10 fields, with the average numbers of invading cells
(±s.d.) plotted (B). Transient transfection of TGM2 siRNA decreased the invasiveness for H1703, as shown in the representative fields of cells
photographed (C) and the average numbers of invading cells plotted (D). Compared with the HCC-95 cells (E), the cell migration was higher in
NCI-H1703 cells having a higher level of TGase 2 (F). The migration was reduced by the treatment of NCI-H1703 with TGM2 siRNA and the
resultant down-regulation of TGase 2 (G and H). The cell migration status was photographed after the indicated time period.
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Page 4 of 10and endothelial cells. Of the 429 NSCLC tissue samples,
93 (21.7%) showed intermediate TGase 2-immunoposi-
tivity and 88 (20.5%), strong TGase 2-immunopositivity
(Table 2).
A comparative analysis of the TGase 2 expression and
clinicopathologic parameters in the 429 NSCLC cases
(Table 2) showed that TGase 2 levels were significantly
higher in adenocarcinoma than in squamous cell carci-
noma (p < 0.001), in females than in males (p < 0.001),
and in nonsmokers than in smokers (p < 0.001). TGase
2 expression was also significantly correlated with T-
stage (p = 0.037), but not with pathologic differentiation
(p = 0.474) or nodal status (p = 0.414), as shown in
Table 2.
Figure 2 Representative photomicrographs of TGase 2 immunostaining in arrayed NSCLC tissues. The left and right columns represent
examples of adenocarcinoma and squamous cell carcinoma showing (A) negative, (B) weak, (C) moderate and (D) strong immunoreactivity,
respectively. Original magnification: ×400.
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Page 5 of 10TGase 2 expression was significantly associated also
with recurrence rate in the operable early-stage NSCLC
cases examined (p = 0.005), as shown in Table 2. Nota-
bly, TGase 2 expression was significantly related to
recurrence in the male (p = 0.011) and non-adenocarci-
noma (p = 0.031) subgroups. By contrast, TGase 2
expression in the adenocarcinoma (p = 0.512) and
female (p = 0.672) subgroups did not show any signifi-
cant association with NSCLC recurrence. In a Kaplan-
Meier plot of the total NSCLC patient population or of
patients with the non-adenocarcinoma subtype, strong
TGase 2 expression was correlated with shorter DFS (p
= 0.011 for NSCLC, and p = 0.014 for the non-adeno-
carcinom subtype by log rank test) (Figure 3). Squamous
cell carcinoma was the major histologic type in the non-
adenocarcinoma subtype of NSCLC. But other histologic
types, including large cell carcinoma, adenosquamous
cell carcinoma, and mucoepidermoid carcinoma, also
were included in the analysis (Table 2).
I nau n i v a r i a t ea n a l y s i s( T a b l e3 ) ,D F Sw a ss i g n i f i -
cantly related to strong TGase 2 expression (p = 0.011)
as well as the clinicopathologic variables including histo-
logic type (p = 0.044), T-stage (p = 0.044), and N-stage
(p < 0.001). In a multivariate analysis considering T-
stage, N-stage, and histological subtype as co-variables
using Cox’s proportional hazard regression model,
TGase 2 expression was significantly related to shorter
DFS (p = 0.029, and HR = 1.554, Table 3).
In the non-adenocarcinoma subtype, strong TGase 2
expression also was significantly associated with shorter
DFS (p = 0.016, Table 1). Moreover, a multivariate ana-
lysis on the non-adenocarcinoma subtype considering
histologic type, differentiation, and clinical stage as co-
variables, also showed strong TGase 2 expression to be
significantly correlated with shorter DFS (p = 0.030, HR
= 2.184), as indicated in Additional File 3, Table S1. In
the male NSCLC subgroups, strong TGase 2 expression
was significantly related to shorter DFS (p = 0.024, data
not shown), but the association, according to the multi-
variate analysis, was not significant.
Discussion
Previous reports [5,9] have posited cisplatin- and doxor-
ubicin-resistance roles for TGase 2 in NSCLC cells. In
the present study, we showed that TGase 2 down-regu-
lation in lung cancer cells inhibited their invasive and
migratory properties via the regulation of MMP-9. In
immunohistochemical staining with Korean early-stage
NSCLC tissues, strong TGase 2-positive cases had sig-
nificantly higher rates of recurrence than TGase 2-nega-
tive cases (p = 0.005), and shorter DFS (p = 0.011).
Moreover, this correlation was statistically significant in
am u l t i v a r i a t ea n a l y s i s( p = 0.029), suggesting that
TGase 2 is an independent prognostic marker for early-
stage NSCLC survival.
The role of TGase 2 as an independent prognostic fac-
tor in surgically curative early-stage cancers appears to
be evident in NSCLC. However, the role of TGase 2 in
whole NSCLC cases is not as strong as in ovarian cancer
[11]. In ovarian cancer, the correlation between survival
and TGase 2 expression was shown to be statistically
significant in a study of only 93 patients [11]. When we
analyzed an identical number of the present NSCLC
population, the association between TGase 2 expression
and survival was not statistically significant. This sug-
gests that TGase 2 might have a correlation with survi-
val only in some subgroup(s) of NSCLC. To address
this, we analyzed the correlation in different NSCLC
subpopulations according to histologic type, gender, and
smoking history. In the analysis, the association was sig-
nificant in the male subgroup and non-adenocarcinoma
subtype, but not in the female subgroup or in the ade-
nocarcinoma subtype. In a multivariate analysis of the
non-adenocarcinoma subtype, a significant association
between TGase 2 expression and DFS was found, sug-
gesting that TGase 2 expression is a prognostic marker
Table 1 Clinicopathologic characteristics of patients with
NSCLC who had undergone complete resection
Variables No. of subjects
(n = 429)
Gender
Male 324 (75.5%)
Female 105 (24.5%)
Age (median, years) 62 (range: 26-81)
Tumor size (median, cm) 3.8 (range: 0.8-20)
Type of surgical resection*
Pneumonectomy 70 (16.4%)
Bilobectomy 32 (7.5%)
Lobectomy 319 (74.7%)
Limited resection 6 (1.4%)
Clinical stage
I 221 (51.5%)
II 102 (23.8%)
III 106 (24.7%)
Adjuvant therapy**
Chemotherapy only 68 (15.9%)
Radiotherapy only 104 (24.2%)
Neither 184 (42.9%)
Both 71 (16.6%)
Median follow-up period (mean ± SD, months) 65.8 (56.3 ± 33.9)
Recurrent cases (recurrence rate) 170 (39.6%)
* Information on the type of surgical resection was not available in two cases.
** Information on radiotherapy was not available in two of the cases treated
with chemotherapy.
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squamous cell carcinoma.
Until recently, the histologic subtyping of NSCLC was
not clinically or therapeutically important. However, the
adenocarcinoma and non-adenocarcinoma subtypes of
NSCLC were suspected as separate entities, owing to
the preferential responses to recently developed agents
in adenocarcinoma [1-3]. This has encouraged research
of new targets in adenocarcinoma NSCLC, and revisits
the importance of subtyping not-otherwise-specified
Table 2 Correlation of TGase 2 over-expression with clinicopathologic variables in patients with resectable early-stage
NSCLC
Variables Total number TGase 2 expression p-value
Negative Intermediate Strong
Histology
Adenocarcinoma 193 (45) 74 (38) 58 (30) 61 (32) <0.001
Squamous carcinoma 198 (46) 155 (78) 26 (13) 17 (9)
Others* 38 (9) 19 (50) 9 (24) 10 (26)
Differentiation**
Well 61 (18) 41 (67) 11 (18) 9 (15) 0.474
Moderate 200 (58) 122 (61) 41 (21) 37 (19)
Poorly 87 (25) 47 (54) 18 (21) 22 (25)
Gender
Male 324 (76) 206 (64) 58 (18) 60 (19) <0.001
Female 105 (24) 42 (40) 35 (33) 28 (27)
Smoking
Nonsmoker 113 (26) 44 (39) 35 (31) 34 (30) <0.001
Ex-smoker 120 (28) 86 (72) 15 (13) 19 (16)
Current Smoker 196 (46) 118 (60) 43 (22) 35 (18)
T-stage***
1 81 (19) 40 (50) 16 (20) 25 (31) 0.037
2 277 (65) 161 (58) 67 (24) 49 (18)
3-4 70 (16) 47 (67) 10 (14) 13 (19)
N-stage
0 257 (60) 148 (58) 55 (21) 54 (21) 0.414
1 93 (22) 53 (57) 17 (18) 23 (25)
2-3 79 (18) 47 (60) 21 (27) 11 (14)
Recurrence event
No 259 (60) 165 (64) 52 (20) 42 (16) 0.005
Yes 170 (40) 83 (49) 41 (24) 46 (27)
Recurrence in male patients
No 203 (47) 141 (69) 33 (16) 29 (14)
Yes 121 (28) 65 (54) 25 (21) 31 (26) 0.011
Recurrence in female patients
No 56 (53) 24 (42) 19 (34) 13 (23) 0.672
Yes 49 (47) 18 (37) 16 (33) 15 (31)
Recurrence in patients with adenocarcinoma
No 102 (53) 43 (42) 29 (28) 30 (29) 0.512
Yes 91 (47) 31 (34) 29 (32) 31 (34)
Recurrence in patients with non-adenocarcinoma
No 157 (67) 122 (78) 23 (15) 12 (8) 0.031
Yes 79 (33) 52 (66) 12 (15) 15 (19)
The significance was tested with Chi-square or Fisher’s exact tests (p). The percentages for the variables are shown within parentheses.
*Large cell lung cancer (13), adenosquamous carcinoma (9), mucoepidermoid carcinoma (8), sarcomatoid carcinoma (3), Pleomorphic carcinoma (2),
lymphepithelioma-like carcinoma (1), adenoid cystic carcinoma (1), and basaloid cell carcinoma (1)
**No information on the pathological differentiation status was available in 81 cases.
***No information on the T-stage was available in one case.
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Page 7 of 10Figure 3 Kaplan-Meier plot of DFS according to different levels of TGase 2 expression in patients in the entire NSCLC population (A)
or in the non-adenocarcinoma subtype (B). For analysis of the immunohistochemical staining, the weak and intermediate TGase 2-expression
groups were combined into an intermediate group. The DFS of the patients with strong TGase 2 expression (red) was significantly shorter (* and
**) than that of the TGase 2-negative patients (blue) in both groups (x-axis: months after surgery; y-axis: DFS probability).
Table 3 Univariate and multivariate analyses of relationship between DSF and TGase 2 expression or clinicopathologic
variables by Cox proportional hazard regression model (n = 429)
Univariate analysis Multivariate analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age 1.001 0.986-1.016 0.889
Gender
Male 1 1
Female 1.107 0.794-1.542 0.549
Histology 0.063 0.072
Adenocarcinoma 1 1 1
Squamous carcinoma 0.718 0.521-0.991 0.044 0.701 0.487-1.008 0.056
Others 1.200 0.705-2.042 0.501 1.214 0.710-2.076 0.478
Differentiation 0.172
Well 1 1
Moderate 1.424 0.862-2.354 0.168
Poorly 1.699 0.977-2.955 0.061
Smoking status 0.165
Non-smoker 1
Ex-smoker 1.060 0.720-1.560 0.769
Current smoker 0.766 0.535-1.096 0.144
T-Stage 0.044 0.012
11 1 1 1
2 1.323 1 0.879-1.992 0.180 1.463 0.962-2.224 0.069
3-4 1.898 1.143-3.150 0.013 2.209 1.308-3.731 0.003
N-Stage <0.001 <0.001
01 1 1 1
1 1.613 1.116-2.330 0.011 1.625 1.118-2.363 0.011
2-3 2.121 1.459-3.084 <0.001 2.074 1.422-3.025 <0.001
TGase 2 expression 0.039 0.086
Negative 1 1 1 1
Intermediate 1.230 0.846-1.789 0.277 1.111 0.752-1.642 0.597
Strong 1.595 1.112-2.287 0.011 1.554 1.046-2.311 0.029
In the multivariate analysis, variables including histology, T-stage and N-stage (those showing p < 0.10 in the univariate analysis) were considered.
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Page 8 of 10bronchial biopsy specimens [15]. However, the molecu-
lar targets in the non-adenocarcinoma subtype have not
been well studied, and new targeted drug development
in this subtype has been quite limited. The difference in
therapeutic response might be related to the origin of
cell types and to the subsequent molecular differences
in the course of cancer progression. In this context, our
finding of a specific association between TGase 2
expression and DFS in the non-adenocarcinoma subtype
might point to TGase 2 as a molecular target in the
non-adenocarcinoma subtype of NSCLC, which includes
squamous cell carcinoma.
The enhanced migratory or invasive properties of
TGase 2 expression might be related to the high binding
affinity of TGase 2 to cell adhesion molecules such as
fibronectin and integrin [16-19]. The interaction between
TGase 2 and cell adhesion molecules in relation to inva-
sion and metastasis has been further investigated in
breast and ovarian cancers [12,13]. TGase 2-mediated
induction of EMT along with the over-expression of var-
ious transcription repressors such as Snail, Zeb1, Zeb2
and Twist1 also has been reported, suggesting that TGase
2 is a key molecule involved in metastasis via EMT [20].
However, in the present study, TGase 2 down-regulation
in a squamous lung cancer cell line did not afftect the
level of EMT markers, suggesting the induction of
NSCLC invasion might not be via EMT pathway. In addi-
tion, high expression of TGase 2 in NSCLC can enhance
the apoptotic threshold via the induction of NF-B,
enabling survival of migrating cancer cells in the face of
harsh micro-environmental stresses during the metastatic
process. In the process, intracellular TGase 2 cross-links
t h ei n h i b i t o r ys u b u n i ta of nuclear factor (I-Ba), thus
releasing NF-Bf r o mi t sb i n d i n gw i t hI - Ba [21,22].
Although the invasive property was shown to be related
to TGase 2 expression in squamous NSCLC cell lines via
the regulation of MMP-9 in the present study, the reason
that TGase 2 expression has an impact on survival or
recurrence only in the non-adenocarcinoma subtype
remains to be revealed.
Conclusion
This study showed a significant association between
TGase 2 expression and recurrence or shorter DFS,
implicating TGase 2 as a prognostic marker in non-ade-
nocarcinoma NSCLC. Recurrence or shorter survival in
cases with higher TGase 2 expression might be related
to the fact that TGase 2 over-expression enhances the
invasive and migratory properties of NSCLC cells. The
present study might also suggest that TGase 2 is a
molecular target for the treatment of the non-adenocar-
cinoma subtype, which might be of importance with
regard to the clinical application of TGase 2 inhibitor
therapy.
Additional material
Additional File 1: Figure S1. TGase 2 and NF-B expression in
NSCLC cells. H1703 showed higher level of TGM2 or TGase 2 than HCC-
95, and down-regulation of TGM2 in the H1703 cell decreased NF-B
activity.
Additional file 2: Figure S2. The relationship between TGase 2
expression and MMP-9 activity in squamous lung cancer cell lines.
Relationship between TGase 2 expression and matrix metalloproteinases
(MMPs) or epithelial mesenchymal transition (EMT) markers was tested,
and it was shown that only MMP-9 has a positive correlation with TGase
2 expression, suggesting that TGase 2’s role in invasion and migration
might be via the regulation of MMP-9.
Additional file 3: Table S1. Univariate and multivariate analyses of
relationship between DFS and clinicopathologic variables or TGase
2 expression by Cox proportional hazard regression model in non-
adenocarcinoma patients with NSCLC. A multivariate analysis on the
non-adenocarcinoma subtype considering histologic type, differentiation,
and clinical stage as co-variables, also showed strong TGase 2 expression
to be significantly correlated with shorter DFS.
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